Abstract Before the introduction of prostate MRI, prostate cancer screening relied on prostate-specific antigen (PSA) testing followed by a systematic biopsy. Although this approach reduced prostate cancer mortality in large, randomized screening trials, its net benefit was questionable because of substantial overdiagnosis. In response, more precise screening tools have been developed. Diagnostic studies demonstrate that MRI has a high sensitivity for clinically significant prostate cancer and a low sensitivity for low-grade cancer, making it well-suited as a triage before biopsy. Using MRI as the primary screening test increases detection of potentially clinically significant cancer, while sequential strategies—such as those used in the STHLM3-MRI trial—reduce the number of MRI scans, unnecessary biopsies and low-grade cancer diagnoses with maintained detection of clinically significant cancer. Several ongoing randomized trials now incorporate PSA-triggered MRI in repeated screening rounds. The Gothenburg 2 trial has reported that its MRI-targeted biopsy pathway halves low-grade cancer detection but misses a few clinically significant cancers. Proscreen evaluates a screening pathway with an ancillary kallikrein test to select men for MRI, PROBASE start age 45 years, and large-scale initiatives—such as organized prostate cancer testing (OPT) programs—evaluate real-world feasibility. Key challenges include optimizing MRI protocols, improving consistency in image interpretation, and reducing false-positive findings, particularly in younger men. Centralized reading, AI support, and refined risk stratification may enhance scalability. Accumulating evidence from ongoing trials and population-based programs suggests that MRI-based screening strategies improve the benefit-to-harm ratio in prostate cancer screening. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> This special report summarizes the evidence from ongoing and completed clinical trials on prostate cancer screening using MRI. <Emphasis Type="BoldItalic">Findings</Emphasis> Across diagnostic and randomized screening trials, MRI-based pathways reduce low-grade cancer detection and biopsy rates while maintaining detection of clinically significant prostate cancer. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> MRI-based screening improves the benefit–harm balance by avoiding unnecessary biopsies and overdiagnosis while maintaining early detection of aggressive prostate cancer, enabling safer, more precise population-level screening for men.

Ongoing and completed clinical trials on prostate cancer screening using MRI

期刊论文
出版模式：

开放获取
发表日期：

2026年4月16日

查看全文

Jonas Wallström,
Fredrik Jäderling,
Fredrik Langkilde,
Rebecka Arnsrud Godtman,
Ola Bratt,
Erik Thimansson

摘要

Abstract

Before the introduction of prostate MRI, prostate cancer screening relied on prostate-specific antigen (PSA) testing followed by a systematic biopsy. Although this approach reduced prostate cancer mortality in large, randomized screening trials, its net benefit was questionable because of substantial overdiagnosis. In response, more precise screening tools have been developed. Diagnostic studies demonstrate that MRI has a high sensitivity for clinically significant prostate cancer and a low sensitivity for low-grade cancer, making it well-suited as a triage before biopsy. Using MRI as the primary screening test increases detection of potentially clinically significant cancer, while sequential strategies—such as those used in the STHLM3-MRI trial—reduce the number of MRI scans, unnecessary biopsies and low-grade cancer diagnoses with maintained detection of clinically significant cancer. Several ongoing randomized trials now incorporate PSA-triggered MRI in repeated screening rounds. The Gothenburg 2 trial has reported that its MRI-targeted biopsy pathway halves low-grade cancer detection but misses a few clinically significant cancers. Proscreen evaluates a screening pathway with an ancillary kallikrein test to select men for MRI, PROBASE start age 45 years, and large-scale initiatives—such as organized prostate cancer testing (OPT) programs—evaluate real-world feasibility. Key challenges include optimizing MRI protocols, improving consistency in image interpretation, and reducing false-positive findings, particularly in younger men. Centralized reading, AI support, and refined risk stratification may enhance scalability. Accumulating evidence from ongoing trials and population-based programs suggests that MRI-based screening strategies improve the benefit-to-harm ratio in prostate cancer screening.

Key Points

Question This special report summarizes the evidence from ongoing and completed clinical trials on prostate cancer screening using MRI.

Findings Across diagnostic and randomized screening trials, MRI-based pathways reduce low-grade cancer detection and biopsy rates while maintaining detection of clinically significant prostate cancer.

Clinical relevance MRI-based screening improves the benefit–harm balance by avoiding unnecessary biopsies and overdiagnosis while maintaining early detection of aggressive prostate cancer, enabling safer, more precise population-level screening for men.